This phenomenon may possibly be due to GBE1 knockdown, which suppressed tumor development by non-immune pathways leading to the upregulation of PD-L1 expression on A549 cells, and simultaneously reduced tumor growth at a rate similar to that seen in the group that received anti-PD-L1 alone (Fig. 6b). The gene discussed is GBE1; the disease is neoplasm.